Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Peptides

Tesamorelin 5 mg

$101Per Unit

GHRH analog with validated sequence and purity. Supplied with comprehensive analytical documentation for research use.

Lot TESA2025-07A · COA on request
Lyophilized peptide
2–8°C

5 × $101.00 = $505.00 $328.25 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

Tesamorelin 5 mg

$328.25 for 5 · 35% off

Research use only
Tesamorelin 5 mg research packaging
Lyophilized peptide
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot TESA2025-07A) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

Tesamorelin

Regulatory status
FDA-approved medicine (Egrifta, Nov 2010) for excess abdominal fat in people with HIV-associated lipodystrophy.
Strongest evidence
Approved drug backed by randomized trials
Overview

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates the body's own growth-hormone release.

What researchers study it for
  • Visceral (abdominal) fat in HIV-associated lipodystrophy
Mechanism

Acts on pituitary GHRH receptors, increasing growth hormone and downstream IGF-1.

Evidence (2)
  1. Human · randomized trial

    Phase 3 trial (NEJM 2007)

    412 patients with HIV and abdominal fat accumulation, 26 weeks. Visceral fat fell 15.2% with tesamorelin versus a 5.0% rise with placebo; IGF-1 rose 81%. More patients on tesamorelin withdrew because of adverse events.[1]

  2. Approved drug

    FDA approval

    Egrifta approved Nov 10, 2010 (Drugs@FDA).[2]

Limitations of the evidence
  • Approved for one specific population; effects outside it are not established.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (2)
  1. 1.Metabolic effects of a growth hormone-releasing factor in patients with HIVFalutz J et al. N Engl J Med. 2007 Human · randomized trial
  2. 2.Egrifta (tesamorelin) - original approval 2010-11-10Drugs@FDA, BLA 022505 Approved drug
Every published studyPubMed search: Tesamorelin(opens in a new tab)Every registered trialClinicalTrials.gov search: Tesamorelin(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.